Inhibition of de novo pyrimidine nucleotide and DNA synthesis and growth of cultured Novikoff rat hepatoma cells and other cell lines by pyrazofurin (NSC 143095).
Pyrazofurin (PYF), a C-riboside, inhibited the replication of cultured Novikoff rat hepatoma cells, HeLa cells, and mouse L-cells at concentrations as low as 0.1 to 10 muM, but Novikoff cells were more sensitive than the cells of the other two cell lines. Inhibition of cell replication was completely prevented by the presence of 0.1 to 1 mM uridine in the medium, and partly by the presence of other pyrimidine, but not purine nucleosides. A 2- to 4-hr treatment of the cells with 10 muM PYF resulted in a 2-fold increase in the rate of incorporation of uridine into the acid-soluble pool and nucleic acids, while the rate of incorporation of adenosine into RNA was reduced about 85%. The incorporation of adenosine and deoxyuridine into DNA were reduced about 85 and 50%, respectively. The results are consistent with the view that PYF inhibits the de novo synthesis of pyrimidine nucleosides. The inhibition of cell replication seems to be due mainly to an inhibition of DNA rather than RNA synthesis, resulting from a rapid depletion of the pyrimidine deoxynucleotide pool, since addition of thymidine and deoxycytidine reversed the inhibition of DNA synthesis and cell replication by PYF. PYF must enter the cells to exert its toxicity since the toxicity of PYF was reduced 70 to 80% by the presence of 8 muM Persantin, a potent inhibitor of the facilitated and simple diffusion of various substrates, in the medium. If PYF is incorporated via normal nucleoside salvage pathways, its affinity for the nucleoside transport system(s) and kinases, must be low since, even at a concentration of 1 mM, it had only a slight effect on the initial rates of incorporation of various nucleosides into the nucleotide pool.
D000241:Adenosine / Q000378:metabolism; D000577:Amides; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D006528:Carcinoma, Hepatocellular / Q000378:metabolism*; D002455:Cell Division / Q000187:drug effects*; D002478:Cells, Cultured; D004247:DNA / Q000096:biosynthesis*; D004273:DNA, Neoplasm / Q000096:biosynthesis; D003843:Deoxycytidine Monophosphate / Q000494:pharmacology; D004176:Dipyridamole / Q000494:pharmacology; D006367:HeLa Cells / Q000187:drug effects*; D007739:L Cells / Q000187:drug effects*; D008113:Liver Neoplasms / Q000378:metabolism; D009374:Neoplasms, Experimental / Q000378:metabolism; D011720:Pyrazoles; D011742:Pyrimidine Nucleotides / Q000096:biosynthesis*; D012313:RNA / Q000096:biosynthesis; D012263:Ribonucleosides / Q000494:pharmacology*; D012266:Ribose; D013936:Thymidine / Q000494:pharmacology; D014529:Uridine / Q000378:metabolism
D000577:Amides; D000900:Anti-Bacterial Agents; D004273:DNA, Neoplasm; D011720:Pyrazoles; D011742:Pyrimidine Nucleotides; D012263:Ribonucleosides; D003843:Deoxycytidine Monophosphate; C002997:pyrazofurin; D012313:RNA; D004176:Dipyridamole; D012266:Ribose; D004247:DNA; D000241:Adenosine; D013936:Thymidine; D014529:Uridine